Company intelligence / Profile preview

Cao Pharmaceuticals Inc.

Webster, Texas, United Statescaopharmaceuticals.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

Completed Phase 1 FDA human trial for CZ48 which proved to have very low to no toxicity. In laboratory trials with nude mice, CZ48 totally inhibited 28 out of 29 human tumors for ten different types of cancer. Phase 2 trials were scheduled to start in Q1 2018, with specific DSRCT trials hoped to begin in 2020[1][4][7]

Therapeutic areas: Women's HealthOncologyNephrology
Modalities: Small moleculesCPT (camptothecin) derivatives
Industry: Biotech

Drug pipeline

1 asset

camptothecin-20-O-propionate

Beyond the preview

Go deeper on Cao Pharmaceuticals Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cao Pharmaceuticals Inc..

Explore the full profile